Stem Cell Related Patent Number US6946445

Therapeutic chemokine receptor antagonists

Clark-Lewis, Ian; Vancouver, Canada
Gong, Jiang-Hong; Vancouver, Canada
Duronio, Vincent; Delta, Canada
Clark-Lewis, Ian; Vancouver, Canada
Gong, Jiang-Hong; Vancouver, Canada
Duronio, Vincent; Delta, Canada

This invention provides a variety of therapeutic uses for CXCR4 antagonists, which are typically used for reducing interferon gamma production by T-cells in the treatment of cancer and of autoimmune diseases such as multiple sclerosis, and for the inhibition of angiogenesis. This invention provides corresponding methods of medical treatment, in which a therapeutic dose of a CXCR4 antagonist is administered in a pharmacologically acceptable formulation and with an excipient or carrier, the exact nature of which is disclosed. The CXCR4 antagonists for use in this invention may be peptide compounds comprising a substantially purified peptide fragment, modified fragment, analogue or pharmacologically acceptable salt of SDF-1.

Application Number: US1999000646192

Date Filed: 02/12/99

Dated Published: 09/20/05

Assignee: The University of British Columbia, Vancouver, Canada